Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Report Examines Industry Trends, Growth Drivers And Future Outlook

The next-generation sequencing (NGS)-based molecular diagnostics sector is on the brink of substantial growth, propelled by rapid technological advancements and expanding applications in healthcare. This market is evolving quickly as innovations like artificial intelligence and portable sequencing devices reshape the landscape, promising enhanced diagnostic accuracy and accessibility. Below, we explore the market's projected size, key players, prevailing trends, and important segments shaping its future.

Projected Growth and Market Size of the Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market
The market for NGS-based molecular diagnostics is set for notable expansion, expected to reach a valuation of $3.23 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 7.3%. Factors driving this increase include advances such as the integration of AI and machine learning into diagnostic processes, the rise of cloud-based genomic platforms, the introduction of portable and point-of-care sequencing devices, a growing focus on personalized medicine, and strategic collaborations between diagnostic companies and biotechnology firms. Key trends anticipated during this period involve AI-assisted diagnostics, cloud genomic analytics, portable sequencing technology, bioinformatics pipeline integration, and rapid detection of disease markers.

Download a free sample of the Next-Generation Sequencing (NGS)-Based Molecular Diagnostics market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28281&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Leading Industry Players in the Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market
Several prominent companies are recognized as major contributors to the NGS-based molecular diagnostics field. These include Thermo Fisher Scientific, Siemens Healthineers AG, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Amoy Diagnostics Co. Ltd., Tempus Labs Inc., Myriad Genetics Inc., Epigenomics AG, Precision for Medicine Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., Caris Life Sciences Inc., Foundation Medicine Inc., Oxford Nanopore Technologies Ltd., Freenome Inc., Burning Rock Biotech, Element Biosciences Inc., Asuragen Inc., Bionano Genomics Inc., Genomic Health Inc., and TATAA Biocenter AB.

Strategic Acquisitions Highlighting Market Expansion
In January 2023, Germany-based molecular diagnostics leader QIAGEN NV acquired US-based Verogen Inc., though financial terms were not disclosed. This acquisition aims to reinforce QIAGEN's dominance in the fields of human identification and forensic genomics by incorporating Verogen's specialized NGS technologies into its broader molecular diagnostics portfolio. The move expands QIAGEN's presence in both public sector forensic applications and private sector markets such as genetic genealogy. Verogen focuses specifically on next-generation sequencing solutions tailored for forensic genomic analysis.

View the full Next-Generation Sequencing (NGS)-Based Molecular Diagnostics market report:
https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-ngs-based-molecular-diagnostics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Current Trends Transforming the Next-Generation Sequencing Market
Top players in the NGS-based molecular diagnostics space are increasingly focused on developing advanced NGS panels that improve the precision, accessibility, and speed of genetic testing. These panels target specific gene sets or genomic regions, enabling simultaneous analysis that detects clinically relevant mutations more efficiently.
For example, in April 2024, US-based Pillar Biosciences gained FDA approval for its oncoReveal CDx pan-cancer solid tumor IVD kit. This panel examines 22 clinically important genes in a single multiplex reaction and is designed for use with Illumina's MiSeq Dx platform. It offers a rapid turnaround time of about 48 hours and can process up to 46 clinical samples per run. The oncoReveal CDx includes companion diagnostic claims for KRAS in colorectal cancer treatments targeting EGFR, and EGFR for tyrosine kinase inhibitor therapy in non-small-cell lung cancer, enabling more streamlined and comprehensive genomic profiling to support treatment decisions.

The Largest Market Segment Within Next-Generation Sequencing (NGS)-Based Molecular Diagnostics
This market is segmented by several categories:
1) By Type: Instruments, Reagents and Consumables, Software and Services, Panels and Assays, and Sample Preparation Kits
2) By Application: Microbiology, Infectious Diseases, Oncology, Genetic Tests, and Other Applications
3) By End User: Research Centers and Academic Institutions, Hospitals and Clinical Laboratories, and Other End Users

Further subdivisions include:
- Instruments such as benchtop sequencers, high-throughput sequencers, portable and handheld sequencers, clinical or diagnostic sequencers, automated library preparation systems, and bioinformatics hardware for data analysis.
- Reagents and consumables covering sequencing kits, library preparation reagents, target enrichment reagents, amplification reagents, sequencing flow cells and chips, DNA/RNA extraction reagents, and quality control reagents.
- Software and services including data analysis software, bioinformatics pipelines, cloud genomic platforms, clinical interpretation tools, data storage, custom bioinformatics services, and genomic databases.
- Panels and assays focusing on oncology, infectious diseases, carrier screening, reproductive health, rare diseases or genetic disorders, pharmacogenomics, and whole-exome or whole-genome assays.
- Sample preparation kits such as DNA and RNA extraction kits, library preparation kits, target enrichment kits, amplification and cleanup kits, single-cell preparation kits, and kits for low-input or degraded samples.

Regional Outlook and Growth Trends
As of 2024, North America holds the largest share of the NGS-based molecular diagnostics market. However, the Asia-Pacific region is expected to experience the fastest growth in the coming years due to increasing healthcare investments and adoption of advanced diagnostic technologies. The market overview includes critical regions like Asia-Pacific, Western and Eastern Europe, North America, South America, and the Middle East and Africa, providing a global perspective on market dynamics and trends.

Expanded capabilities in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.